I work at Genentech now! The amount of effort that goes into each release is phenomenal to me.
-- gnat!
Welcome guest, is this your first visit? Click the "Create Account" button now to join.
Results 1 to 15 of 15
Thread: Her-2
Hybrid View
-
10-15-2008, 09:26 AM #1
Pink-haired superheroine
- Join Date
- May 2007
- Location
- San Francisco, CA
- Posts
- 564
-
10-15-2008, 12:11 PM #2
Registered User
- Join Date
- Apr 2008
- Posts
- 18
jobob! thanks for the mini lesson... i had no clue.. but it's interesting to see how people opt out for testing cancer drugs since its cheaper.. i wish there could be one drug- that has one universal purpose- just to cure, with absolutely no side effects or anything
-
10-15-2008, 01:59 PM #3
back of the autobus
- Join Date
- Dec 2003
- Location
- Folsom CA
- Posts
- 5,667
Isn't that what martinis are for ?
Oh, you said no side effects. Nevermind.
2009 Lynskey R230 Houseblend - Brooks Team Pro
2007 Rivendell Bleriot - Rivet Pearl
-
10-16-2008, 12:43 PM #4
Registered User
- Join Date
- Apr 2008
- Posts
- 36
haha true. I guess it's cool that they made a movie from the book..
-
10-17-2008, 02:23 PM #5
Registered User
- Join Date
- Apr 2008
- Posts
- 18
Yeah very curious to see the movie. Its actually airing tomorrow
night on the Lifetime channel. It's called Living Proof...her is all the
information: http://www.mylifetime.com/on-tv/movies/living-proof
Hope its good!
-
10-17-2008, 02:39 PM #6
back of the autobus
- Join Date
- Dec 2003
- Location
- Folsom CA
- Posts
- 5,667
Harry Connick Jr, what's not to like?
I'll be firing up the DVR. I do hope they get the facts right, it drives me nutz when the facts are messed up for the sake of the story.
2009 Lynskey R230 Houseblend - Brooks Team Pro
2007 Rivendell Bleriot - Rivet Pearl
-
10-17-2008, 02:48 PM #7
back of the autobus
- Join Date
- Dec 2003
- Location
- Folsom CA
- Posts
- 5,667
Regarding my previous post about the economics of drug development, I just came across this ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE - News) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer. The trial was fully enrolled in 2007 with 626 patients and compared GVAX immunotherapy to Taxotere® (docetaxel) chemotherapy plus prednisone. The Company terminated the trial based on the results of a previously unplanned futility analysis conducted by the study’s Independent Data Monitoring Committee (IDMC) which indicated that the trial had less than a 30 percent chance of meeting its predefined primary endpoint of an improvement in survival.
... As a result of these circumstances, Cell Genesys will reduce its staff of 290 by approximately 75 percent by year-end with further reductions anticipated in the first half of 2009 as additional activities are phased out.
Such is the world of drug development.
2009 Lynskey R230 Houseblend - Brooks Team Pro
2007 Rivendell Bleriot - Rivet Pearl
Reply With Quote
